Clinical Trial

Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Malignancies

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
(Limit: 5000 characters) The purpose of this phase I clinical study aims to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SYS6055 Injection in participants with relapsed/refractory B-cell malignancies, and to provide evidence for recommending a dosage regimen for subsequent studies.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-19.
Trial Details
NCT Number NCT07493174
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions Relapsed/Refractory B-Cell Malignancies
Enrollment 86 participants
Start Date 2026-04-15
Primary Completion 2028-04-15 (estimated)
Study Completion 2030-04-15 (estimated)
Updated on ClinicalTrials.gov 2026-04-15